Animals treated three times per day with the Company’s Pulsed Electromagnetic Fields device had significantly higher blood flow at day 7 and 14.
LOS ANGELES, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics (OTCQB: ENDV) (“Endonovo” or the “Company”), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of critical limb ischemia (CLI) in mice.
Animals treated three times per day with the Company’s Pulsed Electromagnetic Fields (PEMF) device had significantly higher blood flow (ratio of blood flow of the ischemic limb to blood flow of non-ischemic limb) at day 7 and 14 (57% and 71%, versus 36% and 52%) versus the controls. Furthermore, animals treated with PEMF three times per day had significantly improved foot movement scores and less tissue damage in the ischemic hind limb versus the controls.
Critical Limb Ischemia (CLI) is an advanced stage of Peripheral Artery Disease (PAD), a common vascular disease that affects approximately 200 million people worldwide, where fatty deposits block arteries in the legs, leading to pain, non-healing ulcers, and gangrene. Worldwide, approximately 22-30 million people suffer from CLI, according to The Sage Group. Patients with CLI have a high risk of amputation and death, and patients unsuitable for revascularization are left with no adequate treatment options.
Endonovo Therapeutics is currently developing a pipeline of non-invasive medical devices, Electroceuticals™, for the treatment of vascular diseases, including cardiovascular and cerebrovascular disease. The Company’s Pulsed Electromagnetic Fields (PEMF) technology has been evaluated in a pilot clinical trial in 30 patients with ischemic cardiomyopathy and failed medical therapy and revascularization options (“no option patients”). Patients in the active cohort demonstrated significant improvements in function, including improved Seattle Angina Questionnaire (SAQ) subscales for Anginal Frequency and severity, and Physical Activity. Furthermore, 3 patients in the active cohort had a 12-25% increase in perfusion compared to the sham group.
“We believe our non-invasive medical devices will address significantly unmet medical needs in vascular diseases, including peripheral artery, cardiovascular and cerebrovascular disease,” said Endonovo CEO, Alan Collier.
“Currently up to 40% of patients with critical limb ischemia are not eligible for revascularization and have a high risk of amputation and death within one year of being diagnosed. Our Electroceuticals have demonstrated remarkable results in both animal models and clinical trials in reducing inflammation, improving blood flow and reducing tissue damage, which we believe will save and improve lives, as well as reduce the economic burden of these major diseases,” concluded Mr. Collier.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s non-invasive Electroceutical™ device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company’s non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact: Endonovo Therapeutics, Inc. Mr. Steven Barnes Senior Vice President of Investor Relations (800) 701-1223, Ext. 108 Sbarnes@endonovo.com www.endonovo.com
